Form 4: Unicycive Therapeutics CEO Acquires Stock Options
SEC Form 4
Shalabh K. Gupta, CEO of Unicycive Therapeutics, reports acquisition of stock options.
Summary
- On August 12, 2024, Shalabh K. Gupta, CEO of Unicycive Therapeutics, acquired 232,868 stock options at an exercise price of $0.34.
- These options vest in tranches, with 58,217 vesting on August 12, 2025, and the remaining options vesting monthly thereafter.
- Following this transaction, Gupta directly owns 6,439,505 shares of Unicycive Therapeutics common stock.
- The options expire on August 12, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. The filing simply reports an acquisition of stock options, which could be seen as a positive sign of confidence, but doesn't provide enough information to strongly indicate a positive or negative outlook.
Positives
- The CEO's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.
Stakeholder Impact
- The acquisition of stock options by the CEO may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of stock options acquisition |
| 08/12/2025 | Date when 58,217 stock options vest |
| 08/12/2034 | Expiration date of the stock options |
| 08/14/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.